Our goal is to commercialize medical products that combine therapeutic and diagnostic capabilities, utilizing our smart SINNAIS™ implantable pump to deliver drugs locally, incorporating metronomic and biofeedback capabilities to provide personalized medicine and virtual physician services to afect better outcomes.
8/01/2023
CLINICAL
Cognos validation study of its SINNAIS™ technology successfully completed.
Cognos THX Second Quarter 2023 Financial Results
Date: 06/15/2023
Time: 3:00PM PST
Location: LIVE WebinarSecond Quarter 2023 Financial Results & Operational Highlights 
2023 Annual Meeting of Stockholders
Date: 03/01/2023 Time: 12:00PM PST Location: LIVE WebinarSINNAISTMTechnology Overview with Dr. Thomas Chen
Date: 01/20/2023 Time: 3:00PM PST Location: LIVE WebinarCognos THX Fourth Quarter 2022 Financial Results
Date: 01/15/2023 Time: 3:00PM PST Location: LIVE WebinarSEC Filings
| Form | Description | Date | Format | |
| S-4 | Registration of material information related to the Cognos/Nocturne merger | 08/16/2023 |  HTML |
 PDF |
| S-1 | Initial registration form for new securities offering. | 03/01/2023 | HTML |
PDF |
| 10-Q | Quarterly report which provides a continuing view of a company’s financial position. | 04/15/2023 | HTML |
PDF |
$10.30 USD
Open $7.15
Volume 6.1M
Day’s Range $10.30 – $10.48
Market Cap $695.8M
Governance Documents
Investor Update
If you would like to receive updates and investor notifications from Cognos Therapeutics, including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more, please provide us your email contact information.
Investor Questions
Shareholders seeking information can contact investor relations at (XXX) XXX-XXXX or email us at ir@cognosthx.com For all other inquiries please call (xxx) xxx-xxxx or email us at info@cognosthx.com